RecruitingPhase 2NCT07168317

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

Studying Angioimmunoblastic T-cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Affiliated Hospital of Xuzhou Medical University
Principal Investigator
Wei Sang Doctor
Intervention
tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone(drug)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07168317 on ClinicalTrials.gov

Other trials for Angioimmunoblastic T-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Angioimmunoblastic T-cell lymphoma →

← Back to all trials